This study suggests that TMEM88 may exert tumor-suppressive effects in HCC, potentially through modulation of the GSK-3β/β-catenin pathway, and its higher expression appears to be associated with more favorable outcomes. These findings indicate that TMEM88 could serve as a prognostic biomarker and may have therapeutic relevance, although further validation is required before clinical application.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: